PepGen Faces FDA Partial Hold on FREEDOM2 DM1 Trial, Advances in Multiple Countries
PepGen announces FDA partial clinical hold on FREEDOM2-DM1 trial due to preclinical questions, while gaining clearance in South Korea, Australia, New Zealand.
Feed↓
/ What's going on?
Filter:
Bears Pile Into Blue Owl Capital: Short Interest Hits Record High Amid Stock Plunge
Blue Owl Capital stock has dropped nearly a third in value this year amid private credit worries. Short interest reaches all-time highs as bearish bets surge, with borrowing demand and costs spiking sharply.
DOJ Launches Probe into Fertilizer Giants for Suspected Price-Fixing Collusion
U.S. Justice Department probes Nutrien, Mosaic, CF Industries, Koch & Yara over potential antitrust violations driving up fertilizer prices for farmers. Early-stage inquiry highlights market concentration concerns.
Day One Biopharmaceuticals Stock Jumps on Renewed M&A Rumors
Day One Biopharmaceuticals shares surge 26% to $12.62 amid fresh speculation of a potential buyout.
Perplexity Chooses CoreWeave to Scale AI Inference, Stock Rises
CoreWeave announces multi-year deal to power Perplexity's AI inference on NVIDIA GB200 clusters.
Abercrombie & Fitch Sees Slower Growth Ahead — Builds 15% U.S. Tariff Impact into 2026 Guidance
Abercrombie & Fitch issued a cautious 2026 outlook, projecting 3–5% sales growth after factoring in the full 15% U.S. tariffs. Shares fell 5% in premarket trading.